Sensorion SA (ALSEN PA) stock market data APIs
€0.2107
-0.04(-19%)
as of April 25, 2025
Sensorion SA Financial Data Overview
Sensorion SA, a biotechnology company, develops drug candidates for the treatment of inner ear disorders in France. The company's product portfolio includes SENS-401 SSNHL, which has completed Phase 2b clinical trial for the treatment of Sudden Sensorineural Hearing Loss; SENS-401 CIO that is in Phase 2a clinical trial for the treatment of Cisplatin-Induced Ototoxicity; and SENS-401 Cochlear, which is in Phase 2a clinical which is an orally available small molecule protecting and preserving inner ear tissue from damage, responsible for hearing impairment. It is also developing OTOF-GT (SENS-501), a gene therapy development program that has completed Phase 1/2 clinical trial to restore hearing in people living with Otoferlin deficiency; and GJB2-GT, a gene therapy development program, which is in pre-clinical trial to restore hearing in people living with hearing loss due to mutations in the GJB2 gene. The company was incorporated in 2009 and is headquartered in Montpellier, France.
Prev. Close
0.2107
Open
0.1702
High
0.2088
Low
0.1539
52 wk Range
0.1544-0.97
Market Cap
47 346 K
Shares Outstanding
301 M
Revenue
6 653 K
EPS
0
Beta
1.305
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Sensorion SA data using free add-ons & libraries
Get Sensorion SA Fundamental Data
Sensorion SA Fundamental data includes:
- Net Revenue: 6 653 K
- EBITDA: -27 579 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2023-11-29
- EPS/Forecast: -0.18
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Sensorion SA News
New
Here's What Key Metrics Tell Us About Qorvo (QRVO) Q1 Earnings
Qorvo (QRVO) reported $651.16 million in revenue for the quarter ended June 2023, representing a year-over-year decline of 37.1%. EPS of $0.34 for the same period compares to $2.25 a year ago. The re...
As Two Chip Stocks Report, Our Plans for a Bullpen Name Become Clearer
As we mentioned on today's Action Alerts PLUS Daily Rundown we are seeing AAP Bullpen position Qualcomm move sharply lower largely in response to its outlook for the coming quarters. To be fair, Qualc...
Sensorion Completes a Private Placement of €35 Million Subscribed by Leading US and European Biotech Investors
New investor Redmile Group enters Sensorion’s capital – existing investors Invus and Sofinnova Partners re-invest significantly New financing will enable the Company to extend its cash runway unti...
Qorvo (QRVO) Q1 Earnings Beat Estimates, Revenues Fall Y/Y
Qorvo, Inc. QRVO reported healthy first-quarter fiscal 2024 results, with the bottom and the top line beating the respective Zacks Consensus Estimate. Demand softness in various end markets, owing ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
